• News
  • SAN DIEGO
  • Health

Halozyme Therapeutics secures $20 million loan addition

Halozyme Therapeutics Inc. (Nasdaq: HALO) has secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank, the San Diego biopharmaceutical company said Monday.

The company entered into an Amended and Restated Loan and Security Agreement in December 2013, extending the original $30 million term loan and providing for an additional $20 million term loan. The agreement brought the total loan balance to $50 million, and the term loan was fully drawn at close on Dec. 27. It has a maturity date of Jan. 1, 2018.

Proceeds from the loan, the company said, will be used for "working capital and other near-term growth initiatives."

As of Dec. 31, Halozyme reported having approximately $71 million in cash and cash equivalents.

Halozyme's research is focused primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. The company markets the Hylenex recombinant, a hyaluronidase human injection, and has partnerships with Roche, Pfizer, Baxter, and Intrexon.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!